Sorafenib Terminated Phase 2 Trials for Bladder Cancers Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01215266Sorafenib in Urothelium Cancer of Bladder